Immunotherapy for osteosarcoma

Kenichiro Yahiro, Yoshihiro Matsumoto

研究成果: Contribution to journalArticle査読

抄録

Osteosarcoma (OS) is the most common malignant bone tumor and often occurs in children. Chemotherapy with methotrexate, cisplatin, doxorubicin, and ifosfamide has greatly improved the prognosis of patients with OS, and most patients have been able to preserve their limbs. However, no progress has been made in the treatment for OS in the past few decades, and the prognosis of patients with metastasis and/or local recurrence remains poor. Therefore, studies aimed at developing new treatment methods for OS are urgently required. Here, we discuss the current status of immunotherapies for OS as well as the current limitations in the field. In recent years, immunotherapy has been shown to be effective for treating several cancers, and its indication is continually increasing. Immunotherapy is also expected to be widely used for treating OS, however, the efficacy of immunotherapy for OS has not been established.

本文言語英語
ページ(範囲)1294-1295
ページ数2
ジャーナルHuman Vaccines and Immunotherapeutics
17
5
DOI
出版ステータス出版済み - 2021
外部発表はい

All Science Journal Classification (ASJC) codes

  • 免疫アレルギー学
  • 免疫学
  • 薬理学

フィンガープリント

「Immunotherapy for osteosarcoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル